About Retrogenix
Company Background
In 2008, pharmaceutical scientist Jim Freeth identified a powerful approach to quickly identify drug-protein interactions using Cell Microarray Technology. Realising the potential importance of this approach to the drug discovery process, Jim formed Retrogenix with fellow scientist Jo Soden to further develop this technology.
In 2009, Retrogenix successfully raised private equity investment to support the development process and secured expertise to help bring the resulting technology to a commercial reality.
Click here to read more
The company has a state-of-the-art laboratory facility, and is based at the Sheffield Bioincubator, UK.
